Dashboard
1
Company has very low debt and has enough cash to service the debt requirements
2
Poor long term growth as Net Sales has grown by an annual rate of 0.19% and Operating profit at 0.67% over the last 5 years
3
The company has declared Negative results for the last 3 consecutive quarters
4
With ROE of 6.89%, it has a very attractive valuation with a 1.10 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 17,879 Million (Small Cap)
16.00
NA
0.00%
-0.62
5.94%
1.28
Revenue and Profits:
Net Sales:
1,757 Million
(Quarterly Results - Jun 2025)
Net Profit:
16 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.12%
0%
1.12%
6 Months
12.68%
0%
12.68%
1 Year
14.66%
0%
14.66%
2 Years
-11.15%
0%
-11.15%
3 Years
23.0%
0%
23.0%
4 Years
23.44%
0%
23.44%
5 Years
37.93%
0%
37.93%
Techno Medica Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.19%
EBIT Growth (5y)
0.67%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.63
Sales to Capital Employed (avg)
0.70
Tax Ratio
23.88%
Dividend Payout Ratio
46.87%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
34.72%
ROE (avg)
7.90%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
1.10
EV to EBIT
5.24
EV to EBITDA
4.87
EV to Capital Employed
1.28
EV to Sales
0.69
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
24.41%
ROE (Latest)
6.89%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
1,757.10
1,999.00
-12.10%
Operating Profit (PBDIT) excl Other Income
20.90
275.00
-92.40%
Interest
0.00
0.00
Exceptional Items
10.00
0.00
Consolidate Net Profit
16.50
173.50
-90.49%
Operating Profit Margin (Excl OI)
-1.60%
125.30%
-12.69%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -12.10% vs 12.91% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -90.49% vs 140.30% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
9,905.90
10,283.90
-3.68%
Operating Profit (PBDIT) excl Other Income
1,400.00
1,953.20
-28.32%
Interest
0.00
0.00
Exceptional Items
16.00
0.00
Consolidate Net Profit
1,004.60
1,348.10
-25.48%
Operating Profit Margin (Excl OI)
131.30%
178.90%
-4.76%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is -3.68% vs 9.78% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -25.48% vs 17.15% in Mar 2024
About Techno Medica Co., Ltd. 
Techno Medica Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






